ClinicalTrials.gg
Active, not recruitingNCT05828511LINKER-MM4Updated Nov 6, 2026

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

A Phase 1/2 interventional study of Linvoseltamab in Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 32 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Updated Nov 6, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.

Enrollment
10th of 16
148 · median 168
Started
2023
with 1 other
Phase 1/2
5 of 16
4 open now
Primary completion
2035-11
later than 13 of 14 live
Registered
3rd of 16
by date
Lead sponsor
10 of 16
Regeneron Pharmaceuticals

Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 10th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 1/2, reaches primary completion later than 13 of the 14 other live ones, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About linvoseltamab

linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing linvoseltamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).

The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.

This study consists of 2 phases:

  • In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
  • In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
  • In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.

The study is looking at several research questions, including:

  • What side effects may happen from taking linvoseltamab?
  • What the right dosing regimen is for linvoseltamab?
  • How many participants treated with linvoseltamab have improvement of their disease and for how long?
  • The effects of linvoseltamab study treatment before and after transplant
  • How much linvoseltamab is in the blood at different times?
  • Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Newly Diagnosed Multiple Myeloma (NDMM)
  • Autologous Stem Cell Transplantation (ASCT)
  • Cluster of Differentiation 3 (CD3)
  • BCMA
  • High Dose chemoTherapy (HDT)
  • International Myeloma Working Group (IMWG)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (ECOG) performance status of 0, 1, or 2
  2. Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
  3. Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
  4. No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent , with as per the protocol
  5. Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
  6. Participants must be age \<70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.

Key Exclusion Criteria:

  1. Receiving any concurrent agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
  2. Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
  3. Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
  4. Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Phase 1 cohorts

    Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve.

    Drug: Linvoseltamab

  • Experimental
    Phase 2 - transplant ineligible cohort

    Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol.

    Drug: Linvoseltamab

  • Experimental
    Phase 2 - transplant eligible cohort

    Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol

    Drug: Linvoseltamab

Interventions

  • Linvoseltamab will be administered by intravenous (IV) infusion

    Also known as: REGN5458, Lynozyfic™

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Phase 1

    Time frame: End of the Observation period; up to day 28

  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  3. Severity of TEAEs

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  4. Incidence of Adverse Events of Special Interest (AESIs)

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  5. Severity of AESIs

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  6. Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria

    Phase 2

    Time frame: Up to 5 years

  7. Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy

    Phase 2 Transplant-eligible cohort

    Time frame: Up to 5 years

  8. Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy

    Phase 2 Transplant-eligible cohort

    Time frame: Up to 5 years

  9. Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II

    Phase 2 Transplant-ineligible cohort

    Time frame: Up to 5 years

  10. Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II

    Phase 2 Transplant ineligible cohort

    Time frame: Up to 5 years

Secondary outcomes

  1. Concentrations of Linvoseltamab in serum

    Phases 1 and 2

    Time frame: Post-Last Linvoseltamab Dose, up to 12 weeks

  2. Concentrations of total soluble B-Cell Maturation Antigen (BCMA)

    Phases 1 and 2

    Time frame: Post-Last Linvoseltamab Dose, up to 12 weeks

  3. Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab

    Phases 1 and 2

    Time frame: Post-Last Linvoseltamab Dose, up to 30 days

  4. Magnitude of ADAs to Linvoseltamab

    Phases 1 and 2

    Time frame: Post-Last Linvoseltamab Dose, up to 30 days

  5. Objective Response Rate (ORR) measured using the IMWG criteria

    Phase 1

    Time frame: Up to 5 years

  6. Duration Of Response (DOR) measured using the IMWG criteria

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  7. Progression-Free Survival (PFS) measured using the IMWG criteria

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  8. Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria

    Phase 1

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  9. Incidence of TEAEs

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  10. Severity of TEAEs

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  11. Incidence of AESIs

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  12. Severity of AESIs

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  13. ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician

    Phase 2

    Time frame: Up to 5 years

  14. MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  15. DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  16. PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  17. Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  18. Time To Response (TTR) as measured using the IMWG criteria

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  19. ORR by risk levels

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  20. MRD-negative status by risk levels

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  21. DOR by risk levels

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  22. TTR by risk levels

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  23. PFS by risk levels

    Phase 2

    Time frame: Post-Last Linvoseltamab Dose, up to 90 days

  24. Incidence of MRD-negative status

    Phase 2

    Time frame: Up to 5 years

  25. Cluster of Differentiation 34+ (CD34+) stem cell yield

    Phase 2 Transplant-eligible cohort

    Time frame: At cycle 4 of induction (each cycle is 28 days long)

  26. Time to neutrophil engraftment

    Phase 2 Transplant-eligible cohort

    Time frame: Up to 100 days post-transplant

  27. Time to platelet engraftment

    Phase 2 Transplant-eligible cohort

    Time frame: Up to 100 days post-transplant

  28. PFS after ASCT followed by 3 cycles of linvoseltamab

    Phase 2 Transplant-eligible cohort

    Time frame: Up to 5 years

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2035, 142 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 142 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
Apr 25, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Nov 2, 2035
CompletionEst.
Nov 2, 2035
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Enrollment
149 (estimated)→148 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    Enrollment 149 (estimated)→148 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05828511
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Dec 19, 2023
Primary completion
Nov 2, 2035 (estimated)
Completion
Nov 2, 2035 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion